DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ABITREXATE
➤ Subscribe for complete access
« Back to Dashboard
All Clinical Trials for Abitrexate
| Trial ID |
Title |
Status |
Sponsor |
Phase |
Start Date |
Summary |
| NCT00003702 ↗ |
Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia |
Completed |
Eastern Cooperative Oncology Group |
Phase 3 |
1999-06-01 |
Randomized phase III trial to compare the effectiveness of methotrexate with that of
dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. It is not yet known whether methotrexate is more effective than dactinomycin in treating
patients with gestational trophoblastic neoplasia.
|
| NCT00003702 ↗ |
Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia |
Completed |
National Cancer Institute (NCI) |
Phase 3 |
1999-06-01 |
Randomized phase III trial to compare the effectiveness of methotrexate with that of
dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. It is not yet known whether methotrexate is more effective than dactinomycin in treating
patients with gestational trophoblastic neoplasia.
|
| NCT00003702 ↗ |
Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia |
Completed |
Gynecologic Oncology Group |
Phase 3 |
1999-06-01 |
Randomized phase III trial to compare the effectiveness of methotrexate with that of
dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. It is not yet known whether methotrexate is more effective than dactinomycin in treating
patients with gestational trophoblastic neoplasia.
|
| >Trial ID |
>Title |
>Status |
>Phase |
>Start Date |
>Summary |
Clinical Trial Conditions for Abitrexate
Condition Name
| Condition Name for Abitrexate |
| Intervention |
Trials |
| Acute Lymphoblastic Leukemia |
24 |
| Untreated Adult Acute Lymphoblastic Leukemia |
13 |
| Leukemia |
13 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Condition MeSH
| Condition MeSH for Abitrexate |
| Intervention |
Trials |
| Leukemia |
54 |
| Leukemia, Lymphoid |
50 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma |
49 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Locations for Abitrexate
Trials by Country
| Trials by Country for Abitrexate |
| Location |
Trials |
| Canada |
142 |
| Australia |
61 |
| New Zealand |
25 |
| Puerto Rico |
14 |
| Japan |
8 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Trials by US State
| Trials by US State for Abitrexate |
| Location |
Trials |
| Texas |
58 |
| Ohio |
42 |
| Pennsylvania |
40 |
| Washington |
40 |
| California |
38 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Progress for Abitrexate
Clinical Trial Phase
| Clinical Trial Phase for Abitrexate |
| Clinical Trial Phase |
Trials |
| Phase 3 |
20 |
| Phase 2/Phase 3 |
1 |
| Phase 2 |
47 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Status
| Clinical Trial Status for Abitrexate |
| Clinical Trial Phase |
Trials |
| Recruiting |
28 |
| Active, not recruiting |
27 |
| Completed |
24 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Sponsors for Abitrexate
Sponsor Name
| Sponsor Name for Abitrexate |
| Sponsor |
Trials |
| National Cancer Institute (NCI) |
78 |
| M.D. Anderson Cancer Center |
24 |
| Children's Oncology Group |
15 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Sponsor Type
| Sponsor Type for Abitrexate |
| Sponsor |
Trials |
| NIH |
83 |
| Other |
80 |
| Industry |
25 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
